Monitor for actual sales volume and pricing under this ATM offering, as sustained dilution could pressure the stock price. The success of the bempikibart clinical program, particularly upcoming topline data in mid-2026, will be a key catalyst that could offset the negative sentiment from dilution.
Price Chart
Executive Summary
Q32 Bio Inc. is conducting an at-the-market (ATM) equity offering of up to $75 million in common stock through Cantor Fitzgerald. The company previously raised $14.2 million under a prior ATM agreement, which has now been terminated. The new offering allows for flexible, opportunistic capital raising based on market conditions, with proceeds intended for working capital and advancing its lead drug candidate, bempikibart, into future clinical trials for alopecia areata.
Key Facts
- Q32 Bio is offering up to $75,000,000 in common stock through an at-the-market (ATM) offering with Cantor Fitzgerald.
- The company has already raised $14,200,000 under a prior ATM agreement, which has been terminated.
- The offering is subject to market conditions, with no minimum amount required, and shares will be sold at prevailing market prices.
- Proceeds will be used for working capital, research, clinical development, and commercialization efforts, primarily for advancing bempikibart.
- Investors purchasing shares will experience immediate dilution of $1.77 per share based on a $6.48 offering price.
- The company is a smaller reporting company with a market cap of $95M and is focused on clinical-stage biologics for autoimmune diseases.
Financial Impact
Up to $75 million in gross proceeds, with net proceeds dependent on the number of shares sold and market prices. Investors will face $1.77 per share dilution based on a $6.48 price.
Risk Factors
- Significant shareholder dilution from the issuance of new shares.
- The company has broad discretion over the use of proceeds, which may not lead to value-enhancing outcomes.
- Future sales under the ATM program could depress the stock price if perceived as a sign of financial need.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-177170 |
| Document: 0001193125-26-177170-index-headers.html | 0001193125-26-177170 |
| Document: 0001193125-26-177170-index.html | 0001193125-26-177170 |
| Document: 0001193125-26-177170.txt | 0001193125-26-177170 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $10.91 $10.47 | ▼ −4.03% | ▼ −4.14% | $8.23 (−24.56%) |
Aug 27, 2026 5w ago | Insider Cluster | $16.15 $12.80 | ▼ −20.74% | ▼ −21.01% | $8.23 (−49.04%) |
Aug 5, 2026 8w ago | 8-K | $16.49 $15.37 | ▼ −6.79% | ▼ −7.14% | $8.23 (−50.09%) |
Jul 15, 2026 11w ago | Press Release | $15.70 $15.08 | ▲ +3.95% | ▲ +2.97% | $8.23 (+47.58%) |
Jul 14, 2026 11w ago | EFFECT | $18.46 $15.04 | ▼ −18.53% | ▼ −17.23% | $8.23 (−55.42%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.23 (−61.51%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.23 (−61.51%) |
Jun 25, 2026 14w ago | S-3 | $13.17 $13.09 | ▼ −0.61% | ▼ −2.77% | $8.23 (−37.51%) |
Jun 2, 2026 17w ago | Insider Cluster | $12.64 $11.89 | ▼ −5.93% | ▼ −2.97% | $8.23 (−34.89%) |
May 5, 2026 21w ago | 8-K | $5.14 $5.81 | ▲ +13.04% | ▲ +11.05% | $8.23 (+60.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access